Syringe Drivers. Back to top

Similar documents
Syringe driver in Palliative Care

Clatterbridge Centre for Oncology

SYRINGE DRIVER MEDICATIONS

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

Using syringe pumps in palliative care

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Algorithms for Symptom Management. In End of Life Care

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

End of life prescribing guidance

Renal Palliative Care Last Days of Life

Syringe Pumps: Guidance for the use with babies, children and young people in the community setting within Worcestershire

CONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

SYRINGE DRIVERS: GUIDANCE FOR THE USE IN THE COMMUNITY and COMMUNITY HOSPITAL SETTING WITHIN WORCESTERSHIRE

Use of the Graseby MS26 Syringe Driver For Palliative Care Within West Lothian

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Supportive Care. End of Life Phase

Care of the Dying Management in Severe Renal Failure

Care in the Last Days of Life

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Care of the Dying Management in Severe Renal Failure

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

McKinley T34 Syringe Pump Policy and Procedure

ADULT SYRINGE DRIVER PROTOCOL (T34)

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Guidelines for Syringe Driver Management in Palliative Care in New Zealand

Symptom Management Guidelines for End of Life Care

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

Care of dying adults in the last days of life. Improving care at the very end of life.

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

POLICY / PROCEDURE FOR THE USE OF THE McKinley T34 SYRINGE DRIVER

Isle of Wight Syringe Driver Compatibility Guidelines

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Specialist Palliative Care Audit and Guidelines Group (SPAGG)

MND Just in Case kit Information for GPs

Conservative Management of Uraemia

First published in 2006 as Guidelines for syringe driver management in palliative care. Reprinted 2007

Palliative care for heart failure patients. Susan Addie

Adult Palliative and Supportive Care: Ambulatory Syringe Pump Policy including Symptom Management Guidelines

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

End Stage Liver Disease Regional Audit Casenote Survey

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

USE OF MCKINLEY T34 SYRINGE DRIVER

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network

SPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation

McKinley T34 Syringe Pump Resource Pack

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

Administration of Drugs via the CME Medical T34 Syringe Driver Standard Operating Procedure

Adult Palliative and Supportive Care: Ambulatory Syringe Driver Policy (including Symptom Management Guidelines)

The last days of life in hospital and at home

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Implementing the recommendation on medication management and symptom control

Guidance for the Use of Subcutaneous Furosemide by Continuous Infusion for Heart Failure in Community Settings

Coversheet for Network Site Specific Group Agreed Documentation

PROCEDURE FOR THE USE OF McKINLEY T34 SYRINGE DRIVER TO DELIVER A CONTINUOUS SUBCUTANEOUS INFUSION IN PALLIATIVE CARE FOR ADULTS

Planning for the future; A guide to symptom control at end of life in advanced dementia

Eastern Health and Social Services Board Palliative Care

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

Palliative Care Impact Survey

MORPHINE ADMINISTRATION

Alternative Routes of Drug Administration (analgesia) Dr Andrew Dickman Consultant Pharmacist

Lothian Palliative Care Guidelines POCKET EDITION 2004

SCHEDULE 2 THE SERVICES

Palliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre

Palliative Care Formulary

Target audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.

survey Parenteral anti-epileptics What is your experience? May July 2015

NURSING PRACTICE GUIDELINES

McKinley T34 Syringe Driver Guidelines for Adult Supportive and Palliative Care

INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT

DRUG COMBINATIONS IN PALLIATIVE CARE: A COMPATIBILITY STUDY

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020

Palliative Care. Anticipatory Prescribing Guidelines & June Gippsland Region Palliative Care Consortium Clinical Practice Group

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY

Palliative Care. Pocketbook 4

What else is new (other symptoms) DR ANDREW DAVIES

SPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

This survey aims to look at individual practice and can be completed by any healthcare professional.

Better Post-Op Pain Control Starts Here

STEP-BY-STEP GUIDE TO SELF-INFUSION. Subcutaneous Administration of GAMMAGARD LIQUID

SHARED CARE GUIDELINE For

Transcription:

Page 1 of 8 Syringe Drivers Introduction Indications for use Advantages Method Siting syringe driver Boost facility Transfer to hospital/hospice syringe driver drugs Drug compatibility P.r.n medication Good practice Advice for patients References Introduction A syringe driver is a light weight battery-operated machine used for providing drugs at a preset rate through a continuous infusion. It is portable and allows delivery of a variety of medications continuously via the subcutaneous route. The Graseby MS26 is used in Manchester; it has a green front section and is calibrated for medication delivery in mm per 24 hours. Indications for use Dysphagia Intractable nausea +/- vomiting link nausea and vomiting Inability to administer medication via oral route i.e. head/neck cancers Gastro -intestinal obstruction Uncontrolled pain Other routes of administration exhausted Malabsorption Profound weakness/cachexia Reduce numerous injections Aversion to oral medication Patient choice End of life link to ICP Advantages of using a syringe driver Control of multiple symptoms with combinations of drugs Continuous infusion avoids peaks and troughs in plasma drug levels Reduces need for repeated injections Facilitates effective management of symptoms at home Setting up a syringe driver (Method) Before starting the procedure the prescription chart or authorising letter should be checked and compatibility ascertained. A useful comprehensive evidence based site can be found at www.palliativedrugs.com,see simplified compatibility chart below or contact Macmillan team for specialist advice. Eqipment Needed

Page 2 of 8 Syringe driver (Graseby MS26) Protective plastic cover Carrying holster 9 volt battery (spare battery should also be available) Rate adjusting key (or paper clip) Appropriately sized luer lock syringes Needles Butterfly infusion set Transparent adhesive dressing to cover butterfly site Appropriate diluent (water for injections or occasionally 0.9% sodium chloride for injections). Prescription chart and/or authorising letter from prescriber Prescribed medication Drug additive labels Prepare the patient & carers by explaining the process, reasons for use and negotiating compliance If symptoms are controlled, start the syringe driver 1 2hrs before the effect of the previous medication is due to wear off. If symptoms are uncontrolled, set up the syringe driver immediately, and give stat SC doses of the same drugs. Luer lock syringes must be used as they stop the giving set and syringe separating if they are unintentionally pulled apart Volume permitting use a 10ml syringe. A 20ml syringe allows greater dilution which reduces: the risk of incompatibility injection site skin reactions. Fill the syringe with drugs and dilute to a maximum length of 60mm. Each time of loading measure from 0 on the syringe driver scale up to the line of the plunger Connect the syringe to the tubing attached to the butterfly cannula and prime the infusion line. This entails pressing the syringe plunger until a drop of fluid is visible at the end of the giving set. For the MS26, the tubing can be primed before measuring the length of the barrel and the rate set to ensure delivery over 24h. After measuring the length of the barrel against the millimetre scale on the syringe driver, the delivery rate is set. The delivery rate is equal to the length of fluid in the syringe. The rate is set by turning the rate setting screws on the front of syringe driver using red screwdriver or paperclip but not a sharp instrument. The drug additive label then needs to be fixed to the barrel of the syringe.

Page 3 of 8 Insert the 9V battery and a shrill audible alarm sounds. The battery should be removed and re-inserted at each change of syringe to check it is working Renew the battery if the indicator light fails to flash every 25 seconds. Each battery should last for about 50 full syringes; the light stops flashing 24h before the battery runs out. Fit the flange of the syringe into the slot provided on the syringe driver and secure with the rubber strap The syringe driver should then be placed in plastic cover. Siting the CSCI Usual sites are 1. the anterior chest wall below clavicle 2. anterolateral aspects of upper arms/anterior surface of the thighs 3. anterior abdominal wall 4. occasionally the back

Page 4 of 8 Sites to avoid: Oedematous limbs/areas Bony prominence or near a joint The upper abdomen in a patient with an enlarged liver Upper chest wall in cachexic patients Skin irradiated within last 8 weeks Skin folds and breast tissue A 25 gauge butterfly needle should be inserted at an angle of 30 45º into SC tissue, The tubing should be secured with a transparent adhesive dressing with a loop to minimise the possibility of pulling out the needle. Care of infusion site The infusion site should be checked at least daily for signs of: Redness Leakage

Page 5 of 8 Back flow If any of the above noted, change the giving set, prime, attach a new butterfly and re-site in a new area. Generally each site should remain suitable for subcutaneous use for approximately 3-5 days. But this is assessed on an indivdiual basis. Re-loading the syringe : Syringe driver should be re-loaded every 24 hours. Check for cloudiness, colour change, precipitation every 24 hours. Use a new syringe each time Check battery is working Frequent re-siting Consider the following: use a larger syringe can dilute mixture and therefore reduce concentration change an irritant drug to less irritant alternative e.g. cyclizine to haloperidol consider alternative hypoallergenic giving set. The MS26 boost facility Although the Graseby MS26 has a boost button it is not recommended for the following reasons: The boost facility lacks a lock-out period. If the boost button is continually depressed, the MS26 will deliver 8 boluses before an alarm sounds and no further boosts are delivered. However, if the button is released, then continually depressed again, a further 8 bolus doses will be administered. Theoretically, this could be continued until the syringe is empty One boost delivers a length of fluid equivalent to 0.23mm which will rarely be an effective analgesic dose. Analgesics are rarely infused alone and additional doses of the other drugs may be undesirable. It may cause stinging at the infusion site. DO NOT USE BOOST BUTTON ENSURE CORRECT S/C BREAKTHROUGH DOSE IS WRITTEN UP (E.G 1/6 24 HOUR DOSE DIAMORPHINE/OR ALTERNATIVE STRONG OPIOID) Transfer of patients into hospital/hospice setting The following information should be sent with the patient:

Page 6 of 8 Time last syringe driver set up (on syringe driver label) 24hour dose prescribed (on syringe driver label) Site of last syringe driver PRN dose(s) given in last 24hours Request to receiving staff to replace driver at next change with their own. Community staff to make arrangements to collect syringe driver when convenient. Common syringe driver drugs Drug 24 hr range Indication Comments Haloperidol 2.5mg-10mgs Anti-emetic Antipsychotic Cyclizine 50-150mgs Anti-emetic Irritation at site Levomepromazine (Nozinan) 6.25-25mgs 25-200mgs Anti-emetic Terminal restlessness Sedating at higher doses Metoclopramide 30-60mgs Anti-emetic Irritation at site Midazolam 10-100mgs Terminal restlessness Anti-convulsants Anxiolytic Glycopyrronium bromide 600-2400mcg Antiimuscarinic for noisy secretions Start asap for noisy secretions Diamorphine No ceiling doses Analgesic Hyoscine butylbromide 20-100mg Intestinal obstruction Noisy secretions Non-sedative Hyoscine hydrobromide 400-1200mcg Noisy secretions Can cause agitation Drug compatibility The following combinations of two drugs are compatible at normal doses and can be mixed with water. Diamorphine Diamorphine Diamorphine Diamorphine Levomepromazine (nozinan) Glycopyrronium Cyclizine Haloperidol Ketorolac Metoclopramide Metoclopramide Midazolam The following combinations of three drugs are compatible at normal doses and can be mixed with water Diamorphine Cyclizine Haloperidol Diamorphine Haloperidol Levomepromazine (nozinan) Diamorphine Haloperidol Midazolam

Page 7 of 8 Diamorphine Hyoscine hydrobromide Levomepromazine (nozinan) Diamorphine Hyoscine hydrobromide Midazolam For more information on drugs used via this route access www.palliativedrugs.com or www.prodigy.nhs.uk N.B. many are used off-label, for further information www.palliative-medicine.org The following drugs are NOT suitable for use in the syringe driver as they are irritant to the skin: Diazepam Prochlorperazine (stemetil) Conversion of Oral Morphine to Subcutaneous Diamorphine opioid conversion chart When a patient is commenced on a continuous subcutaneous infusion, the dose is based on their previous oral morphine/diamorphine requirement. Conversion of oral morphine to s/c diamorphine requirement is calculated at 1/3 e.g. 30mg oral morphine = 10mg s/c diamorphine If you have any queries regarding drug compatibility contact your Macmillan Specialist Palliative Care Team P.R.N medication Recommended practice is to administer via an abbocath canula. Abbocath should be inserted sc into suitable site and secured with a transparent dressing. The end should be sealed using a male luer lock injection port. P.r.n medication can be administered directly through the port using a blue needle (larger/smaller gauge needles can cause stinging). Abbocaths and luer locks are available on order Ref No: FSP 199 ABBOCATH 26G X 19mm. AVON INJECTION PORT MALE LUER LOCK REF R95. Use of abbocath reduces pain/discomfort to patient and ensures direct delivery of medication into subcutaneous tissue Good practice All new staff should ensure they are familiar with the MS26 syringe driver before using. Contact specialist palliative care team for training and/or updates as required. Follow protocol for use. Any queries or advice contact Macmillan team All syringe drivers in use should be serviced regularly

Page 8 of 8 Advice for patients Battery A lways have at least one spare 9V battery Bathing Patients may have a bath or shower but to avoid getting the syringe driver wet as this will cause it to malfunction and/or serious damage. Patients should place the driver on a shelf or chair outside the bath or shower. Avoid soaking the site in the bath. Mobile Phones Avoid using near the driver as this may interfere with the delivery system Clothing Loose clothing is preferable e.g. cardigans. Some patients Choose a dressing gown or clothes with a deep pocket where they place the syringe driver. References Cancernursing.org (2004) Graseby Syringe Drivers in Palliative Care www.cancernursing.org Dickman, A, Littlewood, C, Varga, J (2002). The Syringe Driver. Continuous subcutaneous infusions in palliative care. University Press: Oxford. Help the Hospices (2004) Current Learning in Palliative Care Radcliffe Publishing Twycross, R, Wilcock, A, Charlesworth, S & Dickman, A (2002) Palliative Care Formulary 2 nd Edition. Radcliffe Medical Press: Oxon Twycross, R (2003) Introducing Palliative Care 4 th Edition Radcliffe: Oxford.